MercoPress. South Atlantic News Agency

A personalized mRNA therapy passes a phase 3 melanoma trial for the first time

Pharmaceutical companies Merck, known as MSD outside the United States and Canada, and Moderna announced on Wednesday that their individualized neoantigen therapy, intismeran autogene, met its endpoints in a phase 3 trial in melanoma patients. It is the first positive result at that stage for an mRNA-based cancer treatment. Read full article